Modelling clinical trials in heterogeneous samples

Statistics in Medicine

Volumn 24, Issue 18, 2005, Pages 2765-2775

  Liu, Wenlei ^a   Zhao, Wei ^a   Shaffer, Michele L ^a   Icitovic, Nikolina ^a   Chase, Gary A ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Heterogeneous samples; Two stage clinical trial

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; PLACEBO;

ARTICLE; ASTHMA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL COMPUTING; PHENOTYPE; POPULATION RESEARCH; PROBABILITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

BIOMETRY; CLINICAL TRIALS; DRUG RESISTANCE; DRUG THERAPY; HUMANS; MODELS, STATISTICAL;

EID: 25444467462     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2144     Document Type: Article

References (18)

1. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. American Journal of Respiratory and Critical Care Medicine 2000; 162:75-80.
2. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003; 36(Suppl. 3):S235-S243.
3. Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N, Margel M, Felip E, Mendez P, Garcia-Campelo R. Molecular predictors of response to chemotherapy in lung cancer. Seminars in Oncology 2004; 31(Suppl. 1):20-27.
4. Hill AB. Controlled Clinical Trials. Oxford: Blackwell, 1960.
5. Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail MH, Ware JH. Randomized clinical trials. Perspectives on some recent ideas. New England Journal of Medicine 1976; 295: 74-80.
6. Fisher RA. The Design of Experiments. Oliver and Boyd: Edinburgh, 1935.
7. Gail MH, Wieand S, Piantadosi S. Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates. Biometrika 1984; 71:431-444.
8. Lagakos SW. Effects of mismodelling and mismeasuring explanatory variables on tests of their association with a response variable. Statistics in Medicine 1988; 7:257-274.
9. Tosteson TD, Tsiatis AA. The asymptotic relative efficiency of score tests in a generalized linear model with surrogate covariates. Biometrika 1988; 75:507-514.
10. Begg MD, Lagakos S. On the consequences of model misspecification in logistic regression. Environmental Health Perspectives 1990; 87:69-75.
11. Chastang C, Byar D, Piantadosi S. A quantitative study of the bias in estimating the treatment effect caused by omitting a balanced covariate in survival models. Statistics in Medicine 1988; 7:1243-1255.
12. Schmoor C, Schumacher M. Effects of covariate omission and categorization when analysing randomized trials with the Cox model. Statistics in Medicine 1997; 16:225-237.
13. Ford I, Norrie J. The role of covariates in estimating treatment effects and risk in long-term clinical trials. Statistics in Medicine 2002; 21:2899-2908.
14. Gail MH, Tan WY, Piantadosi S. Tests for no treatment effect in randomized clinical trials. Biometrika 1988; 75:57-64.
15. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statistics in Medicine 2002; 21:2917-2930.
16. Liu W, Icitovic N, Shaffer ML, Chase GA. The impact of population heterogeneity on risk estimation in genetic counseling. BMC Medical Genetics 2004; 5:18.
17. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. Journal of the National Medical Association 2002; 94(Suppl.):1-26.
18. Tanne JH. The new word in designer drugs. British Medical Journal 1998; 316:1930.